WO2007138574A3 - Monitoring responsiveness to and screening for therapeutic compounds that modulat composition and structure of cell membranes - Google Patents

Monitoring responsiveness to and screening for therapeutic compounds that modulat composition and structure of cell membranes Download PDF

Info

Publication number
WO2007138574A3
WO2007138574A3 PCT/IL2007/000633 IL2007000633W WO2007138574A3 WO 2007138574 A3 WO2007138574 A3 WO 2007138574A3 IL 2007000633 W IL2007000633 W IL 2007000633W WO 2007138574 A3 WO2007138574 A3 WO 2007138574A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
cell membranes
screening
modulat
therapeutic compounds
Prior art date
Application number
PCT/IL2007/000633
Other languages
French (fr)
Other versions
WO2007138574A2 (en
Inventor
Yaron Ilan
Original Assignee
Hadasit Med Res Service
Yaron Ilan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL175945A external-priority patent/IL175945A0/en
Application filed by Hadasit Med Res Service, Yaron Ilan filed Critical Hadasit Med Res Service
Publication of WO2007138574A2 publication Critical patent/WO2007138574A2/en
Publication of WO2007138574A3 publication Critical patent/WO2007138574A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to modulation of structure and composition of cell membranes by a given therapeutic compound, preferably, a β-glycolipid and thereby to modulation and treatment of pathologic disorders. More particularly, the invention relates to the use of modulation of structure and composition of immune cell membranes by a candidate therapeutic compound as a diagnostic marker for prediction and monitoring of response to treatment. The invention further provides a method of screening for substances which modulate the structure and composition of cell membranes, as well as compositions and methods using the substances identified by the screening method of the invention, for the treatment of pathologic disorders.
PCT/IL2007/000633 2006-05-25 2007-05-24 Monitoring responsiveness to and screening for therapeutic compounds that modulat composition and structure of cell membranes WO2007138574A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL175945A IL175945A0 (en) 2006-05-25 2006-05-25 Direct and indirect modulation of composition and structure of cell membrane by ??-glycolipids
IL175945 2006-05-25
IL178821A IL178821A0 (en) 2006-05-25 2006-10-23 Direct and indirect modulation of composition and structure of cell membrane by ??-glycolipids
IL178821 2006-10-23

Publications (2)

Publication Number Publication Date
WO2007138574A2 WO2007138574A2 (en) 2007-12-06
WO2007138574A3 true WO2007138574A3 (en) 2009-04-23

Family

ID=38779081

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2007/000633 WO2007138574A2 (en) 2006-05-25 2007-05-24 Monitoring responsiveness to and screening for therapeutic compounds that modulat composition and structure of cell membranes

Country Status (2)

Country Link
IL (1) IL178821A0 (en)
WO (1) WO2007138574A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL187959A0 (en) * 2007-12-06 2008-12-29 Haim Lotan Beta glycolipids for the treatment of calcification related degenerative disorders
JP5465834B2 (en) 2008-01-15 2014-04-09 雪印メグミルク株式会社 Liver function protectant
WO2013049220A1 (en) * 2011-09-30 2013-04-04 University Of Southern California Novel vaccination strategies or therapeutic treatment for influenza virus
ITMI20130513A1 (en) * 2013-04-05 2014-10-06 Euroclone S P A DIAGNOSTIC METHOD FOR AUTOIMMUNE PATHOLOGIES OF THE LIVER
WO2023010117A1 (en) * 2021-07-30 2023-02-02 William Marsh Rice University Identification of pro- and anti-inflammatory lipids relating to immune response to medical implants

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889143A (en) * 1992-04-06 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
US6531453B1 (en) * 1997-04-10 2003-03-11 Kirin Beera Kabushiki Kaisha NKT cell activators containing α-glycosylceramides
US20070117778A1 (en) * 2005-11-24 2007-05-24 Hadasit Medical Research Services & Development Ltd. Beta glycolipids as immuno-modulators
US20080095787A1 (en) * 2006-06-30 2008-04-24 The Scripps Research Institute Adjuvants and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889143A (en) * 1992-04-06 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
US6531453B1 (en) * 1997-04-10 2003-03-11 Kirin Beera Kabushiki Kaisha NKT cell activators containing α-glycosylceramides
US20070117778A1 (en) * 2005-11-24 2007-05-24 Hadasit Medical Research Services & Development Ltd. Beta glycolipids as immuno-modulators
US20080095787A1 (en) * 2006-06-30 2008-04-24 The Scripps Research Institute Adjuvants and methods of use

Also Published As

Publication number Publication date
WO2007138574A2 (en) 2007-12-06
IL178821A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
BRPI0711889B8 (en) method for making simvastatin, composition of matter, method of making huvastatin, method of making simvastatin, and method of making a composition of matter of simvastatin or huvastatin
WO2006009836A3 (en) Tdf-related compounds and analogs thereof
EP2280010A3 (en) Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators
WO2008064353A3 (en) 7,8-saturated-4,5-epoxy-morphinanium analogs
EA201070039A1 (en) SPIROCYCLES AS AN INHIBITORS 11-BETA HYDROXYL-STEROID DEHYDROGENASE TYPE 1
EA200900623A1 (en) BICYCLIC COMPOUNDS AND THEIR APPLICATION AS ANTI-DIABETIC MEANS
WO2008052190A3 (en) Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
WO2010049144A3 (en) Ligands for modulation of orphan receptor-gamma (nr1f3 ) activity
WO2008148801A3 (en) Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
WO2009076454A3 (en) Compounds that modulate intracellular calcium
WO2009114181A3 (en) Substituted heterocycle fused gamma-carbolines solid
WO2007089548A3 (en) Compounds and methods for modulating protein trafficking
WO2008157680A3 (en) Methods and compositions for modulating p300/cbp activity
WO2008070310A3 (en) Method to enhance tissue regeneration
WO2007005887A3 (en) Androgen receptor modulator compounds, compositions and uses thereof
EA200970403A1 (en) BICYCLIC TRIAZOLES AS PROTEINKINASE MODULATORS
WO2007076070A3 (en) Modulators of muscarinic receptors
WO2006076370A3 (en) Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions
WO2009091815A3 (en) Methods for modulating de novo hepatic lipogenesis by modulating xbp-1 activity
WO2006138347A3 (en) Androgen receptor modulator compounds and methods
WO2008089022A3 (en) Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
WO2007138574A3 (en) Monitoring responsiveness to and screening for therapeutic compounds that modulat composition and structure of cell membranes
WO2007035872A3 (en) Tdf-related compounds and analogs thereof
WO2006122769A3 (en) Substituted spiro compounds and their use for producing pain-relief drugs
WO2007100777A3 (en) Methods for the treatment of adhd and related disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07736373

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07736373

Country of ref document: EP

Kind code of ref document: A2